PharmAla Biotech Holdings, Inc. (TSE:MDMA) has released an update.
PharmAla Biotech Holdings Inc. has launched a new online tool to streamline MDMA research by providing researchers with easy access to essential drug data and quality information. This innovation is expected to facilitate the application process for clinical trials and boost the company’s clinical trial sales pipeline. Additionally, PharmAla announced the appointment of William Avery as the new CFO, replacing the outgoing Carmelo Marelli.
For further insights into TSE:MDMA stock, check out TipRanks’ Stock Analysis page.
